1014TiP PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements
Year: 2020
Type: article
Source: Annals of Oncology
Authors: G.K. Abou-Alfa, I. Borbath, A.L. Cohn, L. Goyal, A. Lamarca, T. Macarulla, D-Y. Oh, S. Roychowdhury, S. Sadeghi, R.T. Shroff, M. Howland, A. Li, T. Cho, A. Pande, M. Javle
Institutions: Memorial Sloan Kettering Cancer Center, Cliniques Universitaires Saint-Luc, Rocky Mountain Cancer Centers, Massachusetts General Hospital, The Christie Hospital, The Christie NHS Foundation Trust, Vall d'Hebron Hospital Universitari, Seoul National University, Seoul National University Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University of California, Los Angeles, University of Arizona Cancer Center, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3087796296